Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up

被引:19
作者
Gossec, L.
Le Henanff, A.
Breban, M.
Vignon, E.
Claudepierre, P.
Devauchelle, V.
Wendling, D.
Lespessailles, E.
Euller-Ziegler, L.
Sibilia, J.
Perdriger, A.
Alexandre, C.
Dougados, M.
机构
[1] Univ Paris 05, Hop Cochin, Rheumatol B Unit, AP HP, F-75014 Paris, France
[2] Hop Ambroise Pare, Rheumatol Unit, Boulogne, France
[3] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
[4] Hop Henri Mondor, F-94010 Creteil, France
[5] Cavale Blanche Hosp, Brest, France
[6] Hop Jean Minjoz, F-25030 Besancon, France
[7] Orleans Reg Hosp, Orleans, France
[8] Archet Hosp, Nice, France
[9] Hautepierre Hosp, Strasbourg, France
[10] Sud Hosp, Rennes, France
[11] Bellevue Hosp, St Etienne, France
关键词
ankylosing spondylitis; infliximab; treatment continuation; safety;
D O I
10.1093/rheumatology/kel015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To evaluate the continuation and safety of treatment with infliximab in ankylosing spondylitis (AS) over a 2-yr period. Methods. This study was an open, observational, 2-yr extension study of an open-label study of three induction infusions of infliximab in refractory AS. The fourth infusion was performed only in case of relapse. Thereafter, infliximab was to be administered as needed according to the rheumatologist's opinion; however, for some patients, infusions were performed systematically. Results. None of the 50 recruited patients was lost to follow-up. Thirteen patients (26%) interrupted their treatment by infliximab: four for inefficacy, seven for adverse events, of which four were for allergic reactions to the infusion, and two for other reasons. For all of the 46 patients who had had three infusions judged efficacious and well tolerated, a fourth infusion was performed because of a flare of the disease, after a mean interval of 20.3 +/- 9.9 weeks (range 7.3-57.9). Over the 24 months, the mean interval between infusions was 11.6 +/- 9.0 weeks. This interval was longer when patients were treated only as needed (mean 14.3 +/- 12.1 weeks) than systematically (mean 9.8 +/- 5.7 weeks). Side-effects were similar to those noted in shorter-term studies; seven patients suffered serious adverse events. There were no deaths, no malignancies and no tuberculosis. Conclusion. This study confirms the long-term treatment continuation of infliximab in AS, and shows an acceptable safety profile. It appears that for some patients the disease can be controlled with long intervals between infusions; these findings warrant further studies.
引用
收藏
页码:859 / 862
页数:4
相关论文
共 18 条
[1]   Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].
Baert, F ;
Noman, M ;
Vermeire, S ;
Van Assche, G ;
D'Haens, G ;
Carbonez, A ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608
[2]  
Brandt J, 2000, ARTHRITIS RHEUM-US, V43, P1346, DOI 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO
[3]  
2-E
[4]   Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis [J].
Brandt, J ;
Listing, J ;
Haibel, H ;
Sörensen, H ;
Schwebig, A ;
Rudwaleit, M ;
Sieper, J ;
Braun, J .
RHEUMATOLOGY, 2005, 44 (03) :342-348
[5]  
Brandt J, 2001, ARTHRITIS RHEUM, V44, P2936, DOI 10.1002/1529-0131(200112)44:12<2936::AID-ART483>3.0.CO
[6]  
2-M
[7]   Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Burmester, G ;
Gromnica-Ihle, E ;
Kellner, H ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Sieper, J .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (02) :229-234
[8]   Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis -: An open, observational, extension study of a three-month, randomized, placebo-controlled trial [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Burmester, G ;
Golder, W ;
Gromnica-Ihle, E ;
Kellner, H ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Reddig, J ;
Sieper, J .
ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2224-2233
[9]   Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Golder, W ;
Gromica-Ihle, E ;
Kellner, H ;
Krause, A ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Thriene, W ;
Sieper, J .
LANCET, 2002, 359 (9313) :1187-1193
[10]   Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years [J].
Braun, J ;
Baraliakos, X ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Burmester, G ;
Gromnica-Ihle, E ;
Kellner, H ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Sieper, J .
RHEUMATOLOGY, 2005, 44 (05) :670-676